Should Employers Keep Naloxone at Work? OSHA's New 2026 Opioid Guidance Explained
Quick Answer
On September 24, 2026, OSHA issued a new fact sheet titled "Opioid Overdose Rescue with Reversal Medications" recommending that employers stock FDA-approved opioid reversal medications such as naloxone or nalmefene on site, store them in visible and accessible locations alongside first aid kits and AEDs, and train workers to recognize overdose signs and administer reversal medication while emergency responders are called.
This is guidance — not a new federal regulation — and it does not create new OSHA citation authority or mandate that all employers stock naloxone. But it is a meaningful signal from the federal government that opioid overdose preparedness is now considered part of responsible workplace safety practice. And it connects directly to what drug testing programs are and are not detecting — which is where DrugScreens.com customers need to pay attention.
What OSHA's September 24 Guidance Actually Says
The U.S. Department of Labor's Occupational Safety and Health Administration released a fact sheet on September 24, 2026 as part of the Trump Administration's Great American Recovery Initiative — a government-wide effort focused on addiction treatment and recovery. The fact sheet, titled "Opioid Overdose Rescue with Reversal Medications," provides practical guidance for employers and workers on responding to opioid overdose emergencies in the workplace.
The guidance recommends four core actions for employers:
OSHA's Four Core Opioid Preparedness Recommendations
- Keep FDA-approved reversal medications on hand: OSHA recommends stocking naloxone or nalmefene — medications that attach to opioid receptors and block the effects of opioids including heroin, fentanyl, oxycodone, and morphine, quickly restoring normal breathing during an overdose
- Store them accessibly: OSHA recommends storing opioid overdose reversal medications next to first aid kits and automated external defibrillators (AEDs), away from direct light and excessive heat or cold — treating them as standard emergency equipment, not specialized clinical supplies
- Train workers to recognize overdose signs: Employers should ensure workers can identify the signs of an opioid overdose — pinpoint pupils, unconsciousness, slow or stopped breathing, unresponsiveness
- Train employees to administer reversal medication: While 911 must always be called immediately — because naloxone's effects are temporary and professional medical care is still required — workers trained to administer reversal medication can sustain life in the critical minutes before emergency responders arrive
OSHA also notes that local governments, nonprofits, hospitals, and religious organizations often offer training in administering naloxone or nalmefene. Employers can pair that community-level training with on-site stockpiling to build a complete overdose response capability without significant cost or infrastructure.
This Is Guidance — Not a New Mandate. Here Is Why It Still Matters.
OSHA's fact sheet does not create binding new regulations. It does not hand inspectors authority to cite employers who do not stock naloxone. It is not an emergency temporary standard or a proposed rulemaking. Employers who read past the headline and understand this distinction will make better decisions than those who either panic or dismiss the guidance entirely.
What the guidance does is two things. First, it signals federal intent: the government is now formally telling employers that opioid overdose preparedness belongs in workplace safety programs alongside fire extinguishers, AEDs, and first aid kits. When guidance like this exists and an incident occurs, the absence of reasonable preparedness steps becomes harder to defend in litigation, workers' compensation proceedings, or OSHA general duty clause analyses. Second, it establishes a practical preparedness benchmark that safety professionals, HR teams, and risk managers can use to evaluate and update their programs.
Which Industries Should Pay the Most Attention
OSHA's guidance does not target a specific industry — it is addressed to all employers. But the overdose risk profile is not uniform across the economy, and some industries have more immediate reason to act than others.
Construction is the industry with the highest documented opioid overdose death rate among U.S. workers. Chronic pain, physical injury, and ready access to prescription opioids through medical care for work-related injuries create conditions where opioid use disorder is more prevalent than in the general population. Remote job sites, limited access to emergency medical services, and work environments where a colleague's impairment can be invisible until it becomes a crisis make overdose preparedness particularly consequential in construction.
Manufacturing carries similar risk factors — physical labor, injury-related prescription opioid exposure, and production environments where rapid response time to a medical emergency may be constrained by noise, distance, or equipment. Ohio, Pennsylvania, Michigan, and other industrial Midwest states consistently appear in overdose mortality data with manufacturing workforces as a documented at-risk segment.
Staffing agencies placing workers in construction, warehousing, logistics, and light industrial settings face a compounded challenge: they are placing workers into client sites where they may have no direct control over safety protocols and equipment. Staffing agencies that want to build opioid preparedness into their client relationships need to think about both their own internal policies and how they communicate preparedness expectations to client employers.
Healthcare and long-term care employers operate in environments where overdose risk among staff — not just patients — is a documented reality, and where the clinical infrastructure to respond may still be physically separated from where a workplace incident occurs. Behavioral health facilities and residential treatment providers face a particularly acute version of this challenge.
The Drug Testing Connection — What Testing Does and Does Not Tell You
The OSHA guidance creates a natural bridge to a question that every employer running a drug testing program should be asking: does my current drug test actually detect fentanyl?
Standard opiate (OPI) panels — the opiate analyte in a 5-panel, 6-panel, or 10-panel urine drug test cup — detect morphine and codeine metabolites. They do not detect fentanyl. Fentanyl is a synthetic opioid that does not share the metabolic pathway that OPI immunoassays are designed to detect. A worker who has been using or was exposed to fentanyl can return a negative OPI result on a standard urine drug test cup.
Detecting fentanyl requires a dedicated FTY (fentanyl) analyte — a separate immunoassay strip specifically designed to detect fentanyl and some of its metabolites. The SAFElife 14-panel C-Cup with FTY is the only CLIA-waived urine drug test cup that includes a dedicated fentanyl analyte, making it the appropriate choice for employers who want CLIA-waived documentation with fentanyl detection included. For programs where CLIA-waived classification is not a documentation requirement, the 16-panel SAFElife cup adds EtG alcohol, tramadol, K2, and adulterant checks alongside FTY.
The Workplace Substance Safety Continuum
OSHA's guidance is most useful when it is understood as one component in a broader workplace substance safety continuum — not as a standalone compliance checkbox. Drug testing, written policy, risk identification, overdose preparedness, and employee support resources each play a distinct role. Employers who only think about one piece are missing the full picture.
The Workplace Substance Safety Continuum
Pre-employment · Random · Post-accident
Panel · Occasions · Consequences
Fentanyl panels · Expanded coverage
Naloxone · AED · Training
EAP · MAT referral · Return-to-duty
The drug testing program identifies risk before an incident occurs. The overdose preparedness program responds if an incident occurs despite the testing program. The two are complements, not alternatives. An employer with a robust drug testing program who has not thought about overdose preparedness has a gap. An employer who stocks naloxone but whose drug testing program does not detect fentanyl also has a gap. Neither piece alone constitutes a complete workplace substance safety approach.
For employers looking to build or update their workplace drug testing program alongside OSHA's new overdose preparedness guidance, DrugScreens.com carries CLIA-waived urine cups with and without fentanyl detection, oral fluid saliva kits for post-accident and reasonable-suspicion testing, and dip cards for flexible panel configurations.
New York's Workplace Naloxone Law — A State Mandate Coming December 13
⚠ New York Employers — Action Required Before December 13, 2026
While OSHA's September 24 guidance is advisory, New York is moving to mandate. The New York State Department of Labor published proposed regulations on September 23, 2026 implementing New York's new workplace opioid-antagonist law. Covered private employers would need adequate opioid-antagonist supplies, accessible storage, and at least one trained employee present during business hours. The law takes effect December 13, 2026. Public comments on the proposed rules are open through November 22, 2026. New York employers should begin reviewing the proposed regulations and planning for compliance well before December. New York State Department of Labor
What Employers Should Do Now
Employer Action Checklist — OSHA Opioid Guidance 2026
- Review your current drug test panel: Does it include a dedicated FTY (fentanyl) analyte? If not, evaluate whether your industry and workforce profile warrant adding fentanyl detection to your standard panel
- Assess naloxone stockpiling: Determine whether your organization already has naloxone on site, where it is stored, and whether it is accessible in the locations where an overdose is most likely to occur
- Identify training resources: Locate local naloxone administration training available through government, hospital, or community sources — OSHA notes many of these are available at no cost
- Update written safety programs: If your organization has a written emergency response plan or safety manual, assess whether opioid overdose response procedures should be added
- If you are a New York employer: Review the proposed December 13 regulations now — do not wait for final rules to begin planning
- Consult qualified legal and safety counsel: Evaluate how OSHA's guidance, the updated ANSI/ISEA standard, and applicable state law interact with your organization's existing programs
This content is provided for general informational purposes only and does not constitute legal advice. Any employer or organization considering changes to its workplace safety program, drug testing policy, or emergency response procedures should consult with qualified legal counsel, a certified safety professional, and applicable regulatory authorities before implementing or modifying any program or procedure. OSHA's September 24, 2026 guidance is advisory and does not create new regulatory obligations. New York employers should consult qualified counsel regarding the proposed December 13, 2026 opioid-antagonist regulations.
